A small randomized trial out of São Paulo is giving vitamin D a moment in the spotlight, suggesting that a simple daily pill might help chemotherapy do a better job shrinking breast tumors before surgery. In the study, women who took vitamin D while undergoing neoadjuvant chemotherapy were more likely to reach surgery with no invasive cancer detected than those on a placebo. The finding has sparked interest because vitamin D is inexpensive and already widely used, but oncologists are clear that this is not enough to change standard treatment yet.
What the trial showed
The trial enrolled 80 women aged 45 and older and randomized them to receive either 2,000 IU of cholecalciferol daily or a look-alike placebo during six months of neoadjuvant chemotherapy. Seventy-five women completed both treatment and surgery. In that group, the vitamin D arm reached a pathological complete response (pCR) rate of about 55% compared with roughly 32% in the placebo group.
Blood levels of 25-hydroxyvitamin D rose into the low-adequate range in the supplement group, and logistic analysis linked concentrations above 20 ng/mL with higher odds of pCR. These details were reported in a conference presentation and the published trial record, according to Mastology.
Researchers urge caution
Despite the eye-catching numbers for such a cheap intervention, the investigators and outside specialists are not rushing to declare victory. As one investigator put it, “These are encouraging results that justify a new round of studies with a larger number of participants,” according to ScienceDaily. Local coverage has also stressed that clinicians want larger, multi-center trials before any treatment guidelines budge, as reported by FOX 5 New York.
How it fits with earlier research
This new randomized trial drops into an already complicated evidence pool. Earlier observational and smaller interventional studies have suggested that low vitamin D levels might be linked to weaker chemo responses, but results overall have been mixed.
For example, a retrospective cohort of several hundred patients found that vitamin D deficiency was associated with a lower chance of achieving pCR, according to BMC Cancer. Other trials and pooled analyses, however, have produced variable outcomes, underlining why researchers keep calling for more data rather than quick conclusions.
Safety and what patients should know
The dose used in the trial, 2,000 IU per day, falls well under the U.S. tolerable upper intake level of 4,000 IU for most adults. Even so, experts caution against high, unsupervised dosing or piling on multiple supplements on top of each other. The NIH Office of Dietary Supplements notes that typical recommended intakes for adults are much lower and that supplements should be discussed with a healthcare provider, a point also emphasized by the Harvard T.H. Chan School of Public Health.
What’s next for research and patients
The paper in Nutrition and Cancer has already prompted letters and responses that dig into the study’s design and statistical power. In that correspondence, authors argue that larger, multi-center randomized trials are the logical next step before oncologists consider changing practice, per Nutrition and Cancer.
For now, oncologists and commentators are advising prudence and routine clinical oversight for any supplements used during cancer treatment. That cautious stance is echoed in expert discussion in outlets such as The ASCO Post, where specialists note that even a seemingly simple intervention like vitamin D is unlikely to be one-size-fits-all for patients.
